Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124058573 | 12405857 | 3 | F | 20151223 | 20160826 | 20160526 | 20160830 | EXP | AU-ROCHE-1684451 | ROCHE | 64.08 | YR | F | Y | 58.00000 | KG | 20160830 | MD | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124058573 | 12405857 | 1 | PS | Atezolizumab | ATEZOLIZUMAB | 1 | Intravenous (not otherwise specified) | DATE OF MOST RECENT DOSE PRIOR TO THE EVENT: 10/DEC/2015 (DOSE: 1200 MG) | U | 1005790707 | 761034 | Q3W | |||||||
| 124058573 | 12405857 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | DATE OF MOST RECENT DOSE PRIOR TO THE EVENT: 10/DEC/2015 (DOSE: 870 MG) | U | 0310411328 | 125085 | Q3W | |||||||
| 124058573 | 12405857 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | DATE OF MOST RECENT DOSE PRIOR TO THE EVENT: 10/DEC/2015 (DOSE: 795 MG) | U | 0 | Q3W | ||||||||
| 124058573 | 12405857 | 4 | SS | PACLITAXEL. | PACLITAXEL | 1 | Intravenous (not otherwise specified) | DATE OF MOST RECENT DOSE PRIOR TO THE EVENT: 10/DEC/2015 (DOSE: 320 MG) | U | 0 | Q3W | ||||||||
| 124058573 | 12405857 | 5 | C | RANITIDINE. | RANITIDINE | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 6 | C | LORATADINE. | LORATADINE | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 7 | C | PALONOSETRON | PALONOSETRON | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 8 | C | EMEND | APREPITANT | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 9 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 10 | C | ENDONE | OXYCODONE HYDROCHLORIDE | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 11 | C | ALENDRONATE | ALENDRONATE SODIUM | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 12 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | Unknown | 0 | |||||||||||
| 124058573 | 12405857 | 13 | C | NACL .9% | 2 | Unknown | 0 | 2 | L |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124058573 | 12405857 | 1 | Non-small cell lung cancer |
| 124058573 | 12405857 | 2 | Non-small cell lung cancer |
| 124058573 | 12405857 | 3 | Non-small cell lung cancer |
| 124058573 | 12405857 | 4 | Non-small cell lung cancer |
| 124058573 | 12405857 | 5 | Premedication |
| 124058573 | 12405857 | 6 | Premedication |
| 124058573 | 12405857 | 7 | Premedication |
| 124058573 | 12405857 | 8 | Nausea |
| 124058573 | 12405857 | 10 | Pain management |
| 124058573 | 12405857 | 12 | Neuralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124058573 | 12405857 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124058573 | 12405857 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124058573 | 12405857 | 1 | 20151120 | 0 | ||
| 124058573 | 12405857 | 2 | 20151120 | 0 | ||
| 124058573 | 12405857 | 3 | 20151120 | 0 | ||
| 124058573 | 12405857 | 4 | 20151120 | 0 | ||
| 124058573 | 12405857 | 5 | 20151119 | 0 | ||
| 124058573 | 12405857 | 6 | 20151120 | 0 | ||
| 124058573 | 12405857 | 7 | 20151120 | 0 | ||
| 124058573 | 12405857 | 8 | 20160119 | 0 | ||
| 124058573 | 12405857 | 13 | 20160103 | 20160103 | 0 |